Updated results from the phase 3 ALTA-1L trial of brigatinib (BRG) vs. crizotinib (CRZ) in ALK inhibitor-naive advanced ALK plus NSCLC
Griesinger, F Camidge, DR Kim, HR Ahn, MJ Yang, JCH Han, JY Hochmair, M Lee, H Delmonte, A Compelo, MRG
Griesinger, F
Camidge, DR
Kim, HR
Ahn, MJ
Yang, JCH
Han, JY
Hochmair, M
Lee, H
Delmonte, A
Compelo, MRG
Citations
Altmetric:
Abstract
Description
Date
2020
Publisher
Collections
Keywords
Type
Meetings and Proceedings
Citation
Griesinger F, Camidge DR, Kim HR, Ahn MJ, Yang JCH, Han JY, et al. Updated Results from the Phase 3 ALTA-1L Trial of Brigatinib (BRG) vs. Crizotinib (CRZ) in ALK Inhibitor-Naive Advanced ALK plus NSCLC. Oncology Research and Treatment. 2020;43:232-